Vicky Makker

8.6k total citations · 6 hit papers
180 papers, 4.6k citations indexed

About

Vicky Makker is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Oncology. According to data from OpenAlex, Vicky Makker has authored 180 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 100 papers in Obstetrics and Gynecology, 84 papers in Reproductive Medicine and 66 papers in Oncology. Recurrent topics in Vicky Makker's work include Endometrial and Cervical Cancer Treatments (100 papers), Ovarian cancer diagnosis and treatment (75 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Vicky Makker is often cited by papers focused on Endometrial and Cervical Cancer Treatments (100 papers), Ovarian cancer diagnosis and treatment (75 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Vicky Makker collaborates with scholars based in United States, Spain and Italy. Vicky Makker's co-authors include Ana Oaknin, Carol Aghajanian, Matthew H. Taylor, Corina E. Dutcus, Daniel E. Stepan, Robert Shumaker, Nadeem R. Abu‐Rustum, Kaled M. Alektiar, Drew Rasco and Douglas A. Levine and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Vicky Makker

166 papers receiving 4.6k citations

Hit Papers

Efficacy and Safety of Tr... 2019 2026 2021 2023 2023 2019 2020 2021 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
    2023 432 citations Funda Meric‐Bernstam, Vicky Makker et al. Journal of Clinical Oncology profile →
  2. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
    2019 360 citations Vicky Makker, Marcia S. Brose et al. profile →
  3. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
    2020 359 citations Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology profile →
  4. Endometrial cancer
    2021 340 citations Vicky Makker, Helen Mackay et al. profile →
  5. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
    2020 306 citations Matthew H. Taylor, Vicky Makker et al. Journal of Clinical Oncology profile →
  6. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
    2022 304 citations Ana Oaknin, Domenica Lorusso et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Vicky Makker 2.0k 1.9k 1.5k 975 953 180 4.6k
Edgar Petru 1.2k 0.6× 1.5k 0.8× 1.5k 1.0× 691 0.7× 898 0.9× 222 3.9k
Qin Zhou 1.5k 0.8× 1.7k 0.9× 1.9k 1.2× 947 1.0× 1.9k 2.0× 187 5.4k
Kosei Hasegawa 1.0k 0.5× 1.4k 0.7× 940 0.6× 678 0.7× 508 0.5× 179 3.0k
Antonio Casado 1.4k 0.7× 2.5k 1.3× 2.4k 1.6× 679 0.7× 1.5k 1.5× 178 5.7k
Petronella O. Witteveen 604 0.3× 2.0k 1.1× 1.5k 1.0× 807 0.8× 799 0.8× 95 3.8k
Felix Hilpert 829 0.4× 1.6k 0.8× 2.5k 1.6× 762 0.8× 477 0.5× 172 3.9k
Floor Backes 1.7k 0.9× 895 0.5× 1.6k 1.0× 522 0.5× 381 0.4× 179 3.4k
Amanda Hummer 868 0.4× 1.3k 0.7× 928 0.6× 718 0.7× 661 0.7× 46 3.5k
Anne Floquet 808 0.4× 1.3k 0.7× 1.2k 0.8× 442 0.5× 758 0.8× 170 3.3k
Paul Hoskins 929 0.5× 2.2k 1.2× 1.3k 0.9× 910 0.9× 582 0.6× 131 5.5k

Countries citing papers authored by Vicky Makker

Since Specialization
Citations

This map shows the geographic impact of Vicky Makker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vicky Makker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vicky Makker more than expected).

Fields of papers citing papers by Vicky Makker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vicky Makker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vicky Makker. The network helps show where Vicky Makker may publish in the future.

Co-authorship network of co-authors of Vicky Makker

This figure shows the co-authorship network connecting the top 25 collaborators of Vicky Makker. A scholar is included among the top collaborators of Vicky Makker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vicky Makker. Vicky Makker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Johannet, Paul, M. Herman Chui, Jason Konner, et al.. (2025). Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody–drug conjugate. Gynecologic Oncology. 195. 173–179.
2.
Davidson, Ben, Lora H. Ellenson, Qin Zhou, et al.. (2025). Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma. International Journal of Gynecological Cancer. 35(4). 101651–101651. 1 indexed citations
3.
4.
5.
Green, Angela, Qin Zhou, Alexia Iasonos, et al.. (2024). A phase II study of fulvestrant and abemaciclib in hormone receptor positive advanced or recurrent endometrial cancer.. Journal of Clinical Oncology. 42(16_suppl). 5511–5511. 4 indexed citations
6.
7.
Colomba, Émeline, Domenica Lorusso, Helen Mackay, et al.. (2023). 748P Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775. Annals of Oncology. 34. S512–S513. 2 indexed citations
8.
Shen, Sherry, Weining Ma, David N. Brown, et al.. (2023). HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer. Modern Pathology. 36(11). 100299–100299. 12 indexed citations
9.
Meric‐Bernstam, Funda, Vicky Makker, Ana Oaknin, et al.. (2023). LBA34 Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study. Annals of Oncology. 34. S1273–S1274. 3 indexed citations
10.
Makker, Vicky, Carol Aghajanian, Allen Lee Cohn, et al.. (2023). A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update. Journal of Clinical Oncology. 41(5). 974–979. 25 indexed citations
11.
Colombo, Nicoletta, Domenica Lorusso, Bradley J. Monk, et al.. (2023). Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab. The Oncologist. 29(1). 25–35. 4 indexed citations
12.
13.
Lorusso, Domenica, Vicky Makker, Antonio Casado, et al.. (2022). 2022-RA-653-ESGO The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775. International Journal of Gynecological Cancer. 32. A102–A102. 1 indexed citations
14.
Concin, Nicole, Manish R. Patel, Vicky Makker, et al.. (2022). 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies. International Journal of Gynecological Cancer. 32. A185–A185.
15.
Al-Rawi, Duaa H., Vicky Makker, Britta Weigelt, et al.. (2022). GermlineSMARCA4Deletion as a Driver of Uterine Cancer: An Atypical Presentation. JCO Precision Oncology. 6(6). e2200349–e2200349. 3 indexed citations
16.
Foulsham, William, et al.. (2022). Central retinal vein occlusion in the setting of fibroblast growth factor receptor inhibition. American Journal of Ophthalmology Case Reports. 27. 101657–101657. 4 indexed citations
17.
Brody, Lynn A., Joseph P. Erinjeri, Etay Ziv, et al.. (2021). Safety and Efficacy of Arterially Directed Liver Therapies in the Treatment of Hepatic Metastatic Ovarian Cancer: A Retrospective Single-Institution Study. Journal of Vascular and Interventional Radiology. 32(6). 853–860. 3 indexed citations
18.
Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2020). Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. Journal of Clinical Oncology. 38(26). 2981–2992. 359 indexed citations breakdown →
19.
Grisham, Rachel N., Kathleen N. Moore, Michael S. Gordon, et al.. (2018). Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders. Clinical Cancer Research. 24(22). 5525–5533. 22 indexed citations
20.
Hyman, David M., Naiyer A. Rizvi, Ronald B. Natale, et al.. (2018). Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clinical Cancer Research. 24(12). 2749–2757. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Edgar Petru Breakdown of academic impact, for papers by Qin Zhou Breakdown of academic impact, for papers by Kosei Hasegawa Breakdown of academic impact, for papers by Antonio Casado Breakdown of academic impact, for papers by Petronella O. Witteveen Breakdown of academic impact, for papers by Felix Hilpert Breakdown of academic impact, for papers by Floor Backes Breakdown of academic impact, for papers by Amanda Hummer Breakdown of academic impact, for papers by Anne Floquet Breakdown of academic impact, for papers by Paul Hoskins
Rankless by CCL
2026